Isomorphic Labs, an AI-powered drug discovery company spun out of Google DeepMind, is in advanced discussions to raise over $2 billion in a new funding round, with Thrive Capital expected to lead the financing. This follows Isomorphic Labs’ initiative to launch human trials for fully AI-designed drugs aimed at treating cancer, immune disorders, and complex diseases, highlighting the company’s commitment to innovative healthcare solutions. Additionally, Isomorphic Labs maintains active collaborations with major pharmaceutical companies like Eli Lilly, Novartis, and Johnson & Johnson, which are integral to its ongoing drug development efforts.
Alphabet Inc.: Alphabet Inc. is the parent company of Google DeepMind, driving AI innovations across life sciences through subsidiaries like Calico and support for spinoffs such as Isomorphic Labs. Its healthcare strategy emphasizes accelerating AI from research to practical applications in drug discovery. Alphabet is taking part in Isomorphic Labs’ latest funding round amid ongoing advancements in AI-designed therapies.
Thrive Capital: Thrive Capital is a New York-based venture capital firm founded by Joshua Kushner that invests in transformative technology companies, including recent expansions into sports and entertainment with advisers like former Disney CEO Bob Iger. It has attracted talent from leading AI firms like OpenAI for operator roles. Thrive Capital, which led Isomorphic Labs’ first funding round last year, is positioned to lead the current major financing discussions.
Isomorphic Labs: Isomorphic Labs is a UK-based biotech spinoff from Alphabet’s Google DeepMind that develops AI platforms, including AlphaFold 3 and IsoDDE, to design drugs for undruggable diseases like cancer and immune disorders. It is currently advancing multiple drug programs toward human clinical trials in partnership with major pharmaceutical firms such as Eli Lilly, Novartis, and Johnson & Johnson. The company is in advanced discussions for a significant new funding round led by Thrive Capital, with Alphabet also participating.
Clinical Progress: Isomorphic Labs is preparing to launch human trials for fully AI-designed drugs targeting cancer, immune disorders, and complex diseases.
Investor Activity: Venture firms like Thrive Capital are bolstering AI and biotech portfolios with high-profile hires from OpenAI and entertainment sectors.
Pharma Partnerships: Isomorphic Labs maintains active collaborations with Eli Lilly, Novartis, and Johnson & Johnson on multiple live drug development programs.